Avid Bioservices Inc (CDMO)

[Threes]

I agree a win for the last BOD would not have changed the history which was severely against the them. A win big enough would have to be a blockbuster to carry the day in their favor.
Still if I were in there shoes would have done anything positive to turn the narrative even if it was futile.
So I am leary that there have been advancements in the Exosomes that they could have leveraged.

1. I don't see the advantage to selling just Bavi and holding BB's unless there is another end user that would pay more for the BB's but had no interest in Bavi.
To keep it in house would not be consistent with the current mission as a pure play CDMO.

2. We do not know how the biopsy is new or patentable. Is it intertwined with other related patents.
Shareholders up to now do not get details. Hopefully we will see in the future.

3,Bio may have legs on it's own and in conjunction with other IP . We have no use for it in relation to furthering IP once we are a pure CDMO. So it is on the auction block or put in mothballs pending advancements by a third party. If mothballed it can come from the cellar into a monetized vehicle when applicable.. If there is demand and value has been created that needs to be assessed.

4. What about the imaging PNG, what is the last PR related to imaging. What snags have they hit. What advancements in our favor have occurred. We shareholders clearly have no clue.
Hopefully the new BOD will have and expose the status good and bad.

5. Full acquisition for the IP should be in play and balanced against the value of the IP if sold in pieces.
Full acquisition of AVID does not appear to be on the table. If so why hire the very qualified Mrs K.
Their actions indicate operating the CDMO not selling.
Of course for the right price everything is for sale, but, that would have to be a major inflated number. This team will increase AVID value over the next several years IMO.

As far as overlap of IP in different indications that could easily incorporated in a deal. For instance you can have the PS target and biomarkers , however, we reserve the right to use biomarkers in Exosomes. We also reserve the right to sell or transfer Exosomes to a third party and they inherit the rights to biomarkers ,but, only for use in Exosomes.

It will be up to the current BOD to validate and license, partner , or sell the IP with the best possible return for shareholders.
I hope they would maximize value of Exosomes as with all the IP, since they are aligned with shareholders I expect them to do so.